Dr Janet Scott
- Affiliate (School of Infection & Immunity)
https://orcid.org/0000-0001-8030-5223Biography
Dr Janet Scott is Clinical Lecturer in Infectious Disease at the MRC-University of Glasgow Centre for Virus Research.
Dr Scott trained in Parasitology at the University of Glasgow and holds a PhD in the cellular immune-epidemiology of Schistosomiasis, also from the University of Glasgow, with research in The Gambia, Zimbabwe and Senegal.
After gaining a degree in Medicine at the University of Oxford, she joined the TB Vaccine team as a clinical academic in parallel with her clinical training.
During the Ebola 2014-16 epidemic, she was the clinical lead for the Brincidofovir Trial (Monrovia, Liberia), and Convalescent Plasma (Freetown, Sierra Leone) and was also a member of the clinical trial team for the Tekmira trial.
She is now engaged in the pharmacokinetic/pharmacodynamics analysis of data gathered during these trials and developing methods for dose optimizing drugs for category 4 viruses and studying post Ebola and post COVID syndromes.
Research interests
Dr Scott's main interests are: post viral sequalae focusing on 'LongCOVID' and Post Ebola Syndrome targeting particularly post viral fatigue.
She is also interested in optimising the doses of anti-viral therapeutics using pharmacokinetic and pharmacodynamic in vitro and in silico models with a focus for Lassa and Ebola viruses.
Selected Media
- Voice of America podcast with Joe De Capua discussing Ebola and research stating that 80 per cent of survivors suffer disabilities one year after being discharged from hospital.
Listen here: https://soundcloud.com/post-ebola-syndrome
- BBC World Service audio documentary discussing whether the Ebola Virus can live on undetected (9 October 2015).
Listen here (06:43-11:35): http://www.bbc.co.uk/p0343hb5
- BBC News Hour show discussing if WHO declaring the Ebola epidemic officially over was really the good news the region had been waiting for with flare-ups likely (14 January 2016)
Listen here: http://www.bbc.co.uk/programmes/p03fgzv8
Publications
Number of items: 89.
2024
Liew, F. et al. (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25(4), pp. 607-621. (doi: 10.1038/s41590-024-01778-0) (PMID:38589621)
Sivan, M. et al. (2024) Long COVID clinical severity types based on symptoms and functional disability: A longitudinal evaluation. Journal of Clinical Medicine, 13(7), 1908. (doi: 10.3390/jcm13071908)
Lee, C. et al. (2024) Prevalence of orthostatic intolerance in Long Covid clinic patients: a multicentre observational study. Journal of Medical Virology, 96(3), e29486. (doi: 10.1002/jmv.29486) (PMID:38456315)
Pazukhina, E. et al. (2024) Event rates and incidence of Post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID). BMC Medicine(22), 48. (doi: 10.1186/s12916-023-03221-x) (PMID:38302974) (PMCID:PMC10835884)
Elneima, O. et al. (2024) Cohort profile: Post-hospitalisation COVID-19 study (PHOSP-COVID). International Journal of Epidemiology, 53(1), dyad165. (doi: 10.1093/ije/dyad165) (PMCID:PMC10859139)
Brackel, C. L.H. et al. (2024) International care programs for Pediatric Post-COVID Condition (Long COVID) and the way forward. Pediatric Research, (doi: 10.1038/s41390-023-03015-0) (PMID:38287106) (Early Online Publication)
Cho, S.-M. et al. (2024) Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after COVID-19 hospitalization: An international multicenter prospective observational study. Brain Communications, 6(2), fcae036. (doi: 10.1093/braincomms/fcae036) (PMID:38444907) (PMCID:PMC10914448)
2023
Hastie, C. E. et al. (2023) True prevalence of long-COVID in a nationwide, population cohort study. Nature Communications, 14, 7892. (doi: 10.1038/s41467-023-43661-w) (PMID:38036541) (PMCID:PMC10689486)
Baillie, J.K. et al. (2023) Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. Lancet Respiratory Medicine, 11(11), pp. 1003-1019. (doi: 10.1016/S2213-2600(23)00262-X) (PMID:37748493) (PMCID:PMC7615263)
Taquet, M. et al. (2023) Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nature Medicine, (doi: 10.1038/s41591-023-02525-y) (PMID:37653345) (Early Online Publication)
Jackson, C. et al. (2023) Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. Lancet Respiratory Medicine, 11(8), pp. 673-684. (doi: 10.1016/S2213-2600(23)00124-8) (PMID:37072018) (PMCID:PMC10156429)
Hastie, C. E. et al. (2023) Natural history of long-COVID in a nationwide, population cohort study. Nature Communications, 14, 3504. (doi: 10.1038/s41467-023-39193-y) (PMID:37311808) (PMCID:PMC10263377)
Pauley, E., Drake, T. M., Sigfrid, L., Lone, N., Harrison, E. M., Baillie, J. K., Scott, J. T. , Walsh, T. S., Semple, M. G. and Docherty, A. B. (2023) Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial. Journal of the Intensive Care Society, 24(2), pp. 162-169. (doi: 10.1177/17511437211052226) (PMID:37255989) (PMCID:PMC10225805)
Kartsonaki, C. et al. (2023) Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. International Journal of Epidemiology, 52(2), pp. 355-376. (doi: 10.1093/ije/dyad012) (PMID:36850054) (PMCID:PMC10114094)
Parker, E. et al. (2023) SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: an ISARIC4C prospective study. Frontiers in Immunology, 14, 1146702. (doi: 10.3389/fimmu.2023.1146702) (PMID:37056776) (PMCID:PMC10087108)
Turtle, L. et al. (2023) Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Medicine, 20(1), e1004086. (doi: 10.1371/journal.pmed.1004086) (PMID:36719907) (PMCID:PMC9928075)
2022
Vink, E. et al. (2022) Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study. Open Forum Infectious Diseases, 9(11), ofac531. (doi: 10.1093/ofid/ofac531) (PMID:36381618) (PMCID:PMC9619746)
Hastie, C. E. et al. (2022) Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland Study. Nature Communications, 13, 5663. (doi: 10.1038/s41467-022-33415-5) (PMID:36224173) (PMCID:PMC9556711)
Hastie, C. E. et al. (2022) Do we need consent to obtain consent? Public and participant feedback to using personal health data for recruitment. Journal of Epidemiology and Community Health, 76(8), pp. 697-698. (doi: 10.1136/jech-2022-219214) (PMID:35672086) (PMCID:PMC9279750)
The PHOSP-COVID Collaborative Group, (2022) Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respiratory Medicine, 10(8), pp. 761-775. (doi: 10.1016/S2213-2600(22)00127-8) (PMID:35472304) (PMCID:PMC9034855)
Pazukhina, E. et al. (2022) Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Medicine, 20, 244. (doi: 10.1186/s12916-022-02448-4) (PMID:35794549) (PMCID:PMC9257572)
Munblit, D. et al. (2022) A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respiratory Medicine, 10(7), pp. 715-724. (doi: 10.1016/S2213-2600(22)00169-2) (PMID:35714658) (PMCID:PMC9197249)
Knight, S. R. et al. (2022) Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 77(6), pp. 606-615. (doi: 10.1136/thoraxjnl-2021-217629) (PMID:34810237) (PMCID:PMC8610617)
Stewart, A. et al. (2022) Pandemic, epidemic, endemic: B cell repertoire analysis reveals unique anti-viral responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus. Frontiers in Immunology, 13, 807104. (doi: 10.3389/fimmu.2022.807104) (PMID:35592326) (PMCID:PMC9111746)
Närhi, F. et al. (2022) Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. Lancet Digital Health, 4(4), e220-e234. (doi: 10.1016/S2589-7500(22)00018-8) (PMID:35337642) (PMCID:PMC8940185)
Rosadas, C. et al. (2022) Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 302, 114475. (doi: 10.1016/j.jviromet.2022.114475) (PMID:35077719) (PMCID:PMC8782753)
Munblit, D. et al. (2022) Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Medicine, 20, 50. (doi: 10.1186/s12916-021-02222-y) (PMID:35114994) (PMCID:PMC8813480)
Osmanov, I. M. et al. (2022) Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. European Respiratory Journal, 59(2), 2101341. (doi: 10.1183/13993003.01341-2021) (PMID:34210789) (PMCID:PMC8576804)
Sullivan, M. K. et al. (2022) Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), pp. 271-284. (doi: 10.1093/ndt/gfab303) (PMID:34661677) (PMCID:PMC8788218)
Young, M., Crook, H., Scott, J. and Edison, P. (2022) COVID-19: virology, variants, and vaccines. BMJ Medicine, 1(1), e000040. (doi: 10.1136/bmjmed-2021-000040) (PMID:36936563) (PMCID:PMC9951271)
Reyes, L. F. et al. (2022) Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO Clinical Characterisation Protocol: a prospective, multinational, multicentre, observational study. ERJ Open Research, 8(1), 00552-2021. (doi: 10.1183/23120541.00552-2021) (PMID:35169585) (PMCID:PMC8669808)
2021
Niemi, M. E. K. et al. (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), pp. 472-477. (doi: 10.1038/s41586-021-03767-x) (PMID:34237774) (PMCID:PMC8674144)
Evans, R. A. et al. (2021) Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine, 9(11), pp. 1275-1287. (doi: 10.1016/S2213-2600(21)00383-0) (PMID:34627560) (PMCID:PMC8497028)
Abdukahil, S. A. et al. (2021) COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection, 49(5), pp. 889-905. (doi: 10.1007/s15010-021-01599-5) (PMID:34170486) (PMCID:PMC8231091)
Michelen, M. et al. (2021) Characterising Long Covid: a living systematic review. BMJ Global Health, 6, e005427. (doi: 10.1136/bmjgh-2021-005427) (PMID:34580069) (PMCID:PMC8478580)
Munblit, D. et al. (2021) Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID-19. Clinical and Experimental Allergy, 51(9), pp. 1107-1120. (doi: 10.1111/cea.13997) (PMID:34351016)
Sigfrid, L. et al. (2021) Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Regional Health - Europe, 8, 100186. (doi: 10.1016/j.lanepe.2021.100186) (PMID:34386785) (PMCID:PMC8343377)
Russell, C. D. et al. (2021) Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, 2(8), e354-e365. (doi: 10.1016/S2666-5247(21)00090-2) (PMID:34100002) (PMCID:PMC8172149)
Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)
Gupta, R. K. et al. (2021) Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, 9(4), pp. 349-359. (doi: 10.1016/S2213-2600(20)30559-2) (PMID:33444539) (PMCID:PMC7832571)
Carson, G. and Long Covid Forum Group, (2021) Research priorities for Long Covid: refined through an international multi-stakeholder forum. BMC Medicine, 19(1), 84. (doi: 10.1186/s12916-021-01947-0) (PMID:33785027) (PMCID:PMC8009733)
Scott, J. et al. (2021) ISARIC4C: Multicentre cohort study on symptoms and quality of life following hospitalisation for COVID-19 - preliminary results, 25 February 2021. Documentation. Scientific Advisory Group for Emergencies.
Sigfrid, L. et al. (2021) What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 11(3), e043887. (doi: 10.1136/bmjopen-2020-043887) (PMID:33692181) (PMCID:PMC7948153)
Pairo-Castineira, E. et al. (2021) Genetic mechanisms of critical illness in Covid-19. Nature, 591(7848), pp. 92-98. (doi: 10.1038/s41586-020-03065-y) (PMID:33307546)
Adaken, C. et al. (2021) Ebola virus antibody decay–stimulation in a high proportion of survivors. Nature, 590, pp. 468-472. (doi: 10.1038/s41586-020-03146-y) (PMID:33505020) (PMCID:PMC7839293)
Munblit, D. et al. (2021) The risk of overlooking children during the COVID-19 pandemic: Paediatric Long-COVID may be a ticking time bomb. Lancet Child and Adolescent Health, (Accepted for Publication)
2020
Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)
Knight, S. R. et al. (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. British Medical Journal, 2020, 370. (doi: 10.1136/bmj.m3339) (PMID:32907855)
Swann, O. V. et al. (2020) Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. British Medical Journal, 370, m3249. (doi: 10.1136/bmj.m3249) (PMID:32960186) (PMCID:PMC7488201)
Holgate, S. et al. (2020) Preparing for a challenging winter 2020/21. Technical Report. Academy of Medical Sciences, London.
Harrison, E. M. et al. (2020) Ethnicity and outcomes from COVID-19: the ISARIC CCP-UK prospective observational cohort study of hospitalised patients. SSRN Electronic Journal, (doi: 10.2139/ssrn.3618215) (Submitted)
Akhvlediani, T. et al. (2020) Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, 20(7), pp. 770-772. (doi: 10.1016/S1473-3099(20)30440-0) (PMID:32502433) (PMCID:PMC7266570)
Docherty, A. B. et al. (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. British Medical Journal, 369, m1985. (doi: 10.1136/bmj.m1985) (PMID:32444460)
Scott, J. T. , Sharma, R., Meredith, L. W., Dunning, J., Moore, C. E., Sahr, F., Ward, S., Goodfellow, I. and Horby, P. (2020) Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients. EBioMedicine, 52, 102601. (doi: 10.1016/j.ebiom.2019.102601) (PMID:31953031) (PMCID:PMC7033524)
2018
Howlett, P. J. et al. (2018) Case series of severe neurologic sequelae of Ebola virus disease during epidemic, Sierra Leone. Emerging Infectious Diseases, 24(8), pp. 1412-1421. (doi: 10.3201/eid2408.171367) (PMID:30014839)
Steptoe, P. J. et al. (2018) Multimodal imaging and spatial analysis of Ebola retinal lesions in 14 survivors of Ebola virus disease. JAMA Ophthalmology, 136(6), pp. 689-693. (doi: 10.1001/jamaophthalmol.2018.1248) (PMID:29800941)
Tedder, R. S. et al. (2018) Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. Transfusion, 58(5), pp. 1289-1298. (doi: 10.1111/trf.14580) (PMID:29572862) (PMCID:PMC5947131)
Jagadesh, S., Fletcher, T. E., Sevalie, S., Weigel, R. and Scott, J. T. (2018) Reply to Steptoe et al. Clinical Infectious Diseases, 66(8), p. 1319. (doi: 10.1093/cid/cix980) (PMID:29126296)
Steptoe, P. J., Scott, J. T. , Sahr, F., Vandy, M., Harding, S. P., Beare, N. A. V. and Semple, M. G. (2018) Re: Shantha et al.: Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia (Ophthalmology. 2017;124:170-177). Ophthalmology, 125(3), e19. (doi: 10.1016/j.ophtha.2017.09.009) (PMID:29458832)
Jagadesh, S., Sevalie, S., Fatoma, R., Sesay, F., Sahr, F., Faragher, B., Semple, M. G., Fletcher, T. E., Weigel, R. and Scott, J. T. (2018) Disability among Ebola survivors and their close contacts in Sierra Leone: a retrospective case-controlled cohort study. Clinical Infectious Diseases, 66(1), pp. 131-133. (doi: 10.1093/cid/cix705) (PMID:29020205) (PMCID:PMC5833946)
2017
Steptoe, P. J., Scott, J. T. and Semple, M. G. (2017) Reply to Lee and colleagues—Viral posterior uveitis. Survey of Ophthalmology, 62(4), pp. 404-445. (doi: 10.1016/j.survophthal.2016.12.008) (PMID:28624250)
Steptoe, P. J., Scott, J. T. , Harding, S. P., Beare, N. A. V., Semple, M. G., Vandy, M. J. and Sahr, F. (2017) Ocular complications in survivors of the Ebola outbreak in Guinea. American Journal of Ophthalmology, 181, p. 180. (doi: 10.1016/j.ajo.2017.05.029) (PMID:28760310) (PMCID:PMC5833943)
Steptoe, P. J. et al. (2017) Novel retinal lesion in Ebola survivors, Sierra Leone, 2016. Emerging Infectious Diseases, 23(7), pp. 1102-1109. (doi: 10.3201/eid2307.161608) (PMID:28628441) (PMCID:PMC5512503)
Glynn, J. R. et al. (2017) Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infectious Diseases, 17(6), pp. 645-653. (doi: 10.1016/S1473-3099(17)30111-1) (PMID:28256310)
Scott, J. T. and Semple, M. G. (2017) Ebola virus disease sequelae: a challenge that is not going away. Lancet Infectious Diseases, 17(5), pp. 470-471. (doi: 10.1016/S1473-3099(17)30027-0) (PMID:28094207) (PMCID:PMC5818139)
Howlett, P., Walder, A., Lisk, D., N'jai, A., Lado, M., Brown, C., Sevalie, S., Sesay, F.R., Semple, M.G. and Scott, J.T. (2017) Neurological and Psychiatric Manifestations of Post Ebola Syndrome in Sierra Leone. Spring Meeting for Clinician Scientists in Training 2017, London, UK, 23 Feb 2017. S48. (doi: 10.1016/S0140-6736(17)30444-0)
2016
Glod, J. W. et al. (2016) Experimental treatment of Ebola virus disease with brincidofovir. PLoS ONE, 11(9), e0162199. (doi: 10.1371/journal.pone.0162199) (PMID:27611077) (PMCID:PMC5017617)
Bustinduy, A. L. et al. (2016) Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. mBio, 7(4), e00227-16. (doi: 10.1128/mBio.00227-16) (PMID:27507822) (PMCID:PMC4992966)
Burki, T. K., Crozier, I., Lado, M. and Scott, J. (2016) Post-Ebola syndrome. Lancet Infectious Diseases, 16(7), pp. 780-781. (doi: 10.1016/S1473-3099(15)00259-5) (PMID:27352759)
Scott, J. T. , Sesay, F. R., Massaquoi, T. A., Idriss, B. R., Sahr, F. and Semple, M. G. (2016) Post-Ebola syndrome, Sierra Leone. Emerging Infectious Diseases, 22(4), pp. 641-646. (doi: 10.3201/eid2204.151302) (PMID:26983037) (PMCID:PMC4806950)
Scott, J. T. (2016) Ebola epidemic over but flare-ups likely. [Audio]
2015
Scott, J. T. (2015) Can the Ebola virus live on undetected? [Audio]
2014
Bustinduy, A., King, C., Scott, J. , Appleton, S., Sousa-Figueiredo, J. C., Betson, M. and Stothard, J. R. (2014) HIV and schistosomiasis co-infection in African children. Lancet Infectious Diseases, 14(7), pp. 640-649. (doi: 10.1016/S1473-3099(14)70001-5) (PMID:24747019)
2013
Rowland, R. et al. (2013) Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults. Human Vaccines and Immunotherapeutics, 9(1), pp. 50-62. (doi: 10.4161/hv.22464) (PMID:23143773) (PMCID:PMC3667946)
2012
Scott, J. T. , Scally, C., Peden, N. and Macleod, M. (2012) Voltage-gated potassium channel antibody-related encephalopathy: a case which may extend the documented phenotype of this condition. BMJ Case Reports, 2012, 0720114476. (doi: 10.1136/bcr.07.2011.4476) (PMID:22693327) (PMCID:PMC4543178)
2009
Karita, E. et al. (2009) CLSI-derived hematology and biochemistry reference intervals for healthy adults in Eastern and Southern Africa. PLoS ONE, 4(2), e4401. (doi: 10.1371/journal.pone.0004401) (PMID:19197365) (PMCID:PMC2632744)
2008
Scott, J. (2008) Should I apply for an academic foundation programme? Foundation Years, 4(2), pp. 85-86. (doi: 10.1016/j.mpfou.2008.03.002)
2007
Vereecken, K., Naus, C. W. A., Polman, K., Scott, J. T. , Diop, M., Gryseels, B. and Kestens, L. (2007) Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni. Tropical Medicine and International Health, 12(3), pp. 431-444. (doi: 10.1111/j.1365-3156.2006.01805.x) (PMID:17313515)
2004
Debacker, M., Aguiar, J., Steunou, C., Zinsou, C., Meyers, W. M., Scott, J. T. , Dramaix, M. and Portaels, F. (2004) Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Tropical Medicine and International Health, 9(12), pp. 1297-1304. (doi: 10.1111/j.1365-3156.2004.01339.x) (PMID:15598261)
Debacker, M., Aguiar, J., Steunou, C., Zinsou, C., Meyers, W. M., Guédénon, A., Scott, J. T. , Dramaix, M. and Portaels, F. (2004) Mycobacterium ulcerans Disease (Buruli Ulcer) in Rural Hospital, Southern Benin, 1997–2001. Emerging Infectious Diseases, 10(8), pp. 1391-1398. (doi: 10.3201/eid1008.030886) (PMID:15496239) (PMCID:PMC3320395)
Chatterjee, S., Mbaye, A., Alfidja, A. T., Weyler, J., Scott, J. T. , Van Damme, P., Van De Vijver, K., Deelder, A. and Van Marck, E. A.E. (2004) Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections. Acta Tropica, 90(2), pp. 191-203. (doi: 10.1016/j.actatropica.2003.12.002) (PMID:15177146)
Scott, J. T. , Johnson, R. C., Aguiar, J., Debacker, M., Kestens, L., Guedenon, A., Gryseels, B. and Portaels, F. (2004) Schistosoma haematobium infection and Buruli ulcer. Emerging Infectious Diseases, 10(3), pp. 551-552. (doi: 10.3201/eid1003.020514) (PMID:15116714) (PMCID:PMC3322796)
Scott, J. T. , Vereecken, K., Diakhate, M. M., Vanagt, T., Sambou, V., Diop, M., Ly, A., Vercruysse, J., Gryseels, B. and Kestens, L. (2004) Are the cellular immune responses of children and adults with Schistosoma mansoni infection intrinsically different? Cytokines produced ex vivo in response to antigens and mitogens. Parasite Immunology, 26(1), pp. 29-36. (doi: 10.1111/j.0141-9838.2004.00680.x) (PMID:15198643)
2003
Mduluza, T. et al. (2003) Contrasting cellular responses in Schistosoma haematobium infected and exposed individuals from areas of high and low transmission in Zimbabwe. Immunology Letters, 88(3), pp. 249-256. (doi: 10.1016/S0165-2478(03)00088-9) (PMID:12941484)
Scott, J.T. et al. (2003) Corrigendum. Tropical Medicine and International Health, 8(6), p. 580. (doi: 10.1046/j.1365-3156.2003.01068.x)
Scott, J.T. et al. (2003) Human water contacts patterns in Schistosoma mansoni epidemic foci in northern Senegal change according to age, sex and place of residence, but are not related to intensity of infection. Tropical Medicine and International Health, 8(2), pp. 100-108. (doi: 10.1046/j.1365-3156.2003.00993.x) (PMID:12581433)
2001
Scott, J. T. , Turner, C.M. R., Mutapi, F., Woolhouse, M. E.J., Ndhlovu, P. D. and Hagan, P. (2001) Cytokine responses to mitogen and Schistosoma haematobium antigens are different in children with distinct infection histories. Parasite Immunology, 23(10), pp. 519-526. (doi: 10.1046/j.1365-3024.2001.00409.x) (PMID:11696162)
2000
Scott, J. T. , Turner, C. M. R., Mutapi, F., Woolhouse, M. E.J., Chandiwana, S. K., Mduluza, T., Ndhlovu, P. D. and Hagan, P. (2000) Dissociation of interleukin-4 and interleukin-5 production following treatment for Schistosoma haematobium infection in humans. Parasite Immunology, 22(7), pp. 341-348. (doi: 10.1046/j.1365-3024.2000.00311.x) (PMID:10886718)
1998
Mutapi, F., Ndhlovu, P. D., Hagan, P., Spicer, J. T. , Mduluza, T., Turner, C. M. R., Chandiwana, S. K. and Woolhouse, M. E.J. (1998) Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. Journal of Infectious Diseases, 178(1), pp. 289-293. (doi: 10.1086/517456) (PMID:9652458)
This list was generated on Thu Apr 18 19:13:56 2024 BST.
Number of items: 89.
Articles
Liew, F. et al. (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25(4), pp. 607-621. (doi: 10.1038/s41590-024-01778-0) (PMID:38589621)
Sivan, M. et al. (2024) Long COVID clinical severity types based on symptoms and functional disability: A longitudinal evaluation. Journal of Clinical Medicine, 13(7), 1908. (doi: 10.3390/jcm13071908)
Lee, C. et al. (2024) Prevalence of orthostatic intolerance in Long Covid clinic patients: a multicentre observational study. Journal of Medical Virology, 96(3), e29486. (doi: 10.1002/jmv.29486) (PMID:38456315)
Pazukhina, E. et al. (2024) Event rates and incidence of Post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID). BMC Medicine(22), 48. (doi: 10.1186/s12916-023-03221-x) (PMID:38302974) (PMCID:PMC10835884)
Elneima, O. et al. (2024) Cohort profile: Post-hospitalisation COVID-19 study (PHOSP-COVID). International Journal of Epidemiology, 53(1), dyad165. (doi: 10.1093/ije/dyad165) (PMCID:PMC10859139)
Brackel, C. L.H. et al. (2024) International care programs for Pediatric Post-COVID Condition (Long COVID) and the way forward. Pediatric Research, (doi: 10.1038/s41390-023-03015-0) (PMID:38287106) (Early Online Publication)
Cho, S.-M. et al. (2024) Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after COVID-19 hospitalization: An international multicenter prospective observational study. Brain Communications, 6(2), fcae036. (doi: 10.1093/braincomms/fcae036) (PMID:38444907) (PMCID:PMC10914448)
Hastie, C. E. et al. (2023) True prevalence of long-COVID in a nationwide, population cohort study. Nature Communications, 14, 7892. (doi: 10.1038/s41467-023-43661-w) (PMID:38036541) (PMCID:PMC10689486)
Baillie, J.K. et al. (2023) Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. Lancet Respiratory Medicine, 11(11), pp. 1003-1019. (doi: 10.1016/S2213-2600(23)00262-X) (PMID:37748493) (PMCID:PMC7615263)
Taquet, M. et al. (2023) Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nature Medicine, (doi: 10.1038/s41591-023-02525-y) (PMID:37653345) (Early Online Publication)
Jackson, C. et al. (2023) Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. Lancet Respiratory Medicine, 11(8), pp. 673-684. (doi: 10.1016/S2213-2600(23)00124-8) (PMID:37072018) (PMCID:PMC10156429)
Hastie, C. E. et al. (2023) Natural history of long-COVID in a nationwide, population cohort study. Nature Communications, 14, 3504. (doi: 10.1038/s41467-023-39193-y) (PMID:37311808) (PMCID:PMC10263377)
Pauley, E., Drake, T. M., Sigfrid, L., Lone, N., Harrison, E. M., Baillie, J. K., Scott, J. T. , Walsh, T. S., Semple, M. G. and Docherty, A. B. (2023) Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial. Journal of the Intensive Care Society, 24(2), pp. 162-169. (doi: 10.1177/17511437211052226) (PMID:37255989) (PMCID:PMC10225805)
Kartsonaki, C. et al. (2023) Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. International Journal of Epidemiology, 52(2), pp. 355-376. (doi: 10.1093/ije/dyad012) (PMID:36850054) (PMCID:PMC10114094)
Parker, E. et al. (2023) SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: an ISARIC4C prospective study. Frontiers in Immunology, 14, 1146702. (doi: 10.3389/fimmu.2023.1146702) (PMID:37056776) (PMCID:PMC10087108)
Turtle, L. et al. (2023) Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Medicine, 20(1), e1004086. (doi: 10.1371/journal.pmed.1004086) (PMID:36719907) (PMCID:PMC9928075)
Vink, E. et al. (2022) Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study. Open Forum Infectious Diseases, 9(11), ofac531. (doi: 10.1093/ofid/ofac531) (PMID:36381618) (PMCID:PMC9619746)
Hastie, C. E. et al. (2022) Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland Study. Nature Communications, 13, 5663. (doi: 10.1038/s41467-022-33415-5) (PMID:36224173) (PMCID:PMC9556711)
Hastie, C. E. et al. (2022) Do we need consent to obtain consent? Public and participant feedback to using personal health data for recruitment. Journal of Epidemiology and Community Health, 76(8), pp. 697-698. (doi: 10.1136/jech-2022-219214) (PMID:35672086) (PMCID:PMC9279750)
The PHOSP-COVID Collaborative Group, (2022) Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respiratory Medicine, 10(8), pp. 761-775. (doi: 10.1016/S2213-2600(22)00127-8) (PMID:35472304) (PMCID:PMC9034855)
Pazukhina, E. et al. (2022) Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Medicine, 20, 244. (doi: 10.1186/s12916-022-02448-4) (PMID:35794549) (PMCID:PMC9257572)
Munblit, D. et al. (2022) A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respiratory Medicine, 10(7), pp. 715-724. (doi: 10.1016/S2213-2600(22)00169-2) (PMID:35714658) (PMCID:PMC9197249)
Knight, S. R. et al. (2022) Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 77(6), pp. 606-615. (doi: 10.1136/thoraxjnl-2021-217629) (PMID:34810237) (PMCID:PMC8610617)
Stewart, A. et al. (2022) Pandemic, epidemic, endemic: B cell repertoire analysis reveals unique anti-viral responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus. Frontiers in Immunology, 13, 807104. (doi: 10.3389/fimmu.2022.807104) (PMID:35592326) (PMCID:PMC9111746)
Närhi, F. et al. (2022) Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. Lancet Digital Health, 4(4), e220-e234. (doi: 10.1016/S2589-7500(22)00018-8) (PMID:35337642) (PMCID:PMC8940185)
Rosadas, C. et al. (2022) Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 302, 114475. (doi: 10.1016/j.jviromet.2022.114475) (PMID:35077719) (PMCID:PMC8782753)
Munblit, D. et al. (2022) Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Medicine, 20, 50. (doi: 10.1186/s12916-021-02222-y) (PMID:35114994) (PMCID:PMC8813480)
Osmanov, I. M. et al. (2022) Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. European Respiratory Journal, 59(2), 2101341. (doi: 10.1183/13993003.01341-2021) (PMID:34210789) (PMCID:PMC8576804)
Sullivan, M. K. et al. (2022) Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), pp. 271-284. (doi: 10.1093/ndt/gfab303) (PMID:34661677) (PMCID:PMC8788218)
Young, M., Crook, H., Scott, J. and Edison, P. (2022) COVID-19: virology, variants, and vaccines. BMJ Medicine, 1(1), e000040. (doi: 10.1136/bmjmed-2021-000040) (PMID:36936563) (PMCID:PMC9951271)
Reyes, L. F. et al. (2022) Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO Clinical Characterisation Protocol: a prospective, multinational, multicentre, observational study. ERJ Open Research, 8(1), 00552-2021. (doi: 10.1183/23120541.00552-2021) (PMID:35169585) (PMCID:PMC8669808)
Niemi, M. E. K. et al. (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), pp. 472-477. (doi: 10.1038/s41586-021-03767-x) (PMID:34237774) (PMCID:PMC8674144)
Evans, R. A. et al. (2021) Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine, 9(11), pp. 1275-1287. (doi: 10.1016/S2213-2600(21)00383-0) (PMID:34627560) (PMCID:PMC8497028)
Abdukahil, S. A. et al. (2021) COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection, 49(5), pp. 889-905. (doi: 10.1007/s15010-021-01599-5) (PMID:34170486) (PMCID:PMC8231091)
Michelen, M. et al. (2021) Characterising Long Covid: a living systematic review. BMJ Global Health, 6, e005427. (doi: 10.1136/bmjgh-2021-005427) (PMID:34580069) (PMCID:PMC8478580)
Munblit, D. et al. (2021) Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID-19. Clinical and Experimental Allergy, 51(9), pp. 1107-1120. (doi: 10.1111/cea.13997) (PMID:34351016)
Sigfrid, L. et al. (2021) Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Regional Health - Europe, 8, 100186. (doi: 10.1016/j.lanepe.2021.100186) (PMID:34386785) (PMCID:PMC8343377)
Russell, C. D. et al. (2021) Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, 2(8), e354-e365. (doi: 10.1016/S2666-5247(21)00090-2) (PMID:34100002) (PMCID:PMC8172149)
Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)
Gupta, R. K. et al. (2021) Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, 9(4), pp. 349-359. (doi: 10.1016/S2213-2600(20)30559-2) (PMID:33444539) (PMCID:PMC7832571)
Carson, G. and Long Covid Forum Group, (2021) Research priorities for Long Covid: refined through an international multi-stakeholder forum. BMC Medicine, 19(1), 84. (doi: 10.1186/s12916-021-01947-0) (PMID:33785027) (PMCID:PMC8009733)
Sigfrid, L. et al. (2021) What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 11(3), e043887. (doi: 10.1136/bmjopen-2020-043887) (PMID:33692181) (PMCID:PMC7948153)
Pairo-Castineira, E. et al. (2021) Genetic mechanisms of critical illness in Covid-19. Nature, 591(7848), pp. 92-98. (doi: 10.1038/s41586-020-03065-y) (PMID:33307546)
Adaken, C. et al. (2021) Ebola virus antibody decay–stimulation in a high proportion of survivors. Nature, 590, pp. 468-472. (doi: 10.1038/s41586-020-03146-y) (PMID:33505020) (PMCID:PMC7839293)
Munblit, D. et al. (2021) The risk of overlooking children during the COVID-19 pandemic: Paediatric Long-COVID may be a ticking time bomb. Lancet Child and Adolescent Health, (Accepted for Publication)
Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)
Knight, S. R. et al. (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. British Medical Journal, 2020, 370. (doi: 10.1136/bmj.m3339) (PMID:32907855)
Swann, O. V. et al. (2020) Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. British Medical Journal, 370, m3249. (doi: 10.1136/bmj.m3249) (PMID:32960186) (PMCID:PMC7488201)
Harrison, E. M. et al. (2020) Ethnicity and outcomes from COVID-19: the ISARIC CCP-UK prospective observational cohort study of hospitalised patients. SSRN Electronic Journal, (doi: 10.2139/ssrn.3618215) (Submitted)
Akhvlediani, T. et al. (2020) Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, 20(7), pp. 770-772. (doi: 10.1016/S1473-3099(20)30440-0) (PMID:32502433) (PMCID:PMC7266570)
Docherty, A. B. et al. (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. British Medical Journal, 369, m1985. (doi: 10.1136/bmj.m1985) (PMID:32444460)
Scott, J. T. , Sharma, R., Meredith, L. W., Dunning, J., Moore, C. E., Sahr, F., Ward, S., Goodfellow, I. and Horby, P. (2020) Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients. EBioMedicine, 52, 102601. (doi: 10.1016/j.ebiom.2019.102601) (PMID:31953031) (PMCID:PMC7033524)
Howlett, P. J. et al. (2018) Case series of severe neurologic sequelae of Ebola virus disease during epidemic, Sierra Leone. Emerging Infectious Diseases, 24(8), pp. 1412-1421. (doi: 10.3201/eid2408.171367) (PMID:30014839)
Steptoe, P. J. et al. (2018) Multimodal imaging and spatial analysis of Ebola retinal lesions in 14 survivors of Ebola virus disease. JAMA Ophthalmology, 136(6), pp. 689-693. (doi: 10.1001/jamaophthalmol.2018.1248) (PMID:29800941)
Tedder, R. S. et al. (2018) Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. Transfusion, 58(5), pp. 1289-1298. (doi: 10.1111/trf.14580) (PMID:29572862) (PMCID:PMC5947131)
Jagadesh, S., Fletcher, T. E., Sevalie, S., Weigel, R. and Scott, J. T. (2018) Reply to Steptoe et al. Clinical Infectious Diseases, 66(8), p. 1319. (doi: 10.1093/cid/cix980) (PMID:29126296)
Steptoe, P. J., Scott, J. T. , Sahr, F., Vandy, M., Harding, S. P., Beare, N. A. V. and Semple, M. G. (2018) Re: Shantha et al.: Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia (Ophthalmology. 2017;124:170-177). Ophthalmology, 125(3), e19. (doi: 10.1016/j.ophtha.2017.09.009) (PMID:29458832)
Jagadesh, S., Sevalie, S., Fatoma, R., Sesay, F., Sahr, F., Faragher, B., Semple, M. G., Fletcher, T. E., Weigel, R. and Scott, J. T. (2018) Disability among Ebola survivors and their close contacts in Sierra Leone: a retrospective case-controlled cohort study. Clinical Infectious Diseases, 66(1), pp. 131-133. (doi: 10.1093/cid/cix705) (PMID:29020205) (PMCID:PMC5833946)
Steptoe, P. J., Scott, J. T. and Semple, M. G. (2017) Reply to Lee and colleagues—Viral posterior uveitis. Survey of Ophthalmology, 62(4), pp. 404-445. (doi: 10.1016/j.survophthal.2016.12.008) (PMID:28624250)
Steptoe, P. J., Scott, J. T. , Harding, S. P., Beare, N. A. V., Semple, M. G., Vandy, M. J. and Sahr, F. (2017) Ocular complications in survivors of the Ebola outbreak in Guinea. American Journal of Ophthalmology, 181, p. 180. (doi: 10.1016/j.ajo.2017.05.029) (PMID:28760310) (PMCID:PMC5833943)
Steptoe, P. J. et al. (2017) Novel retinal lesion in Ebola survivors, Sierra Leone, 2016. Emerging Infectious Diseases, 23(7), pp. 1102-1109. (doi: 10.3201/eid2307.161608) (PMID:28628441) (PMCID:PMC5512503)
Glynn, J. R. et al. (2017) Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infectious Diseases, 17(6), pp. 645-653. (doi: 10.1016/S1473-3099(17)30111-1) (PMID:28256310)
Scott, J. T. and Semple, M. G. (2017) Ebola virus disease sequelae: a challenge that is not going away. Lancet Infectious Diseases, 17(5), pp. 470-471. (doi: 10.1016/S1473-3099(17)30027-0) (PMID:28094207) (PMCID:PMC5818139)
Glod, J. W. et al. (2016) Experimental treatment of Ebola virus disease with brincidofovir. PLoS ONE, 11(9), e0162199. (doi: 10.1371/journal.pone.0162199) (PMID:27611077) (PMCID:PMC5017617)
Bustinduy, A. L. et al. (2016) Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. mBio, 7(4), e00227-16. (doi: 10.1128/mBio.00227-16) (PMID:27507822) (PMCID:PMC4992966)
Burki, T. K., Crozier, I., Lado, M. and Scott, J. (2016) Post-Ebola syndrome. Lancet Infectious Diseases, 16(7), pp. 780-781. (doi: 10.1016/S1473-3099(15)00259-5) (PMID:27352759)
Scott, J. T. , Sesay, F. R., Massaquoi, T. A., Idriss, B. R., Sahr, F. and Semple, M. G. (2016) Post-Ebola syndrome, Sierra Leone. Emerging Infectious Diseases, 22(4), pp. 641-646. (doi: 10.3201/eid2204.151302) (PMID:26983037) (PMCID:PMC4806950)
Bustinduy, A., King, C., Scott, J. , Appleton, S., Sousa-Figueiredo, J. C., Betson, M. and Stothard, J. R. (2014) HIV and schistosomiasis co-infection in African children. Lancet Infectious Diseases, 14(7), pp. 640-649. (doi: 10.1016/S1473-3099(14)70001-5) (PMID:24747019)
Rowland, R. et al. (2013) Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults. Human Vaccines and Immunotherapeutics, 9(1), pp. 50-62. (doi: 10.4161/hv.22464) (PMID:23143773) (PMCID:PMC3667946)
Scott, J. T. , Scally, C., Peden, N. and Macleod, M. (2012) Voltage-gated potassium channel antibody-related encephalopathy: a case which may extend the documented phenotype of this condition. BMJ Case Reports, 2012, 0720114476. (doi: 10.1136/bcr.07.2011.4476) (PMID:22693327) (PMCID:PMC4543178)
Karita, E. et al. (2009) CLSI-derived hematology and biochemistry reference intervals for healthy adults in Eastern and Southern Africa. PLoS ONE, 4(2), e4401. (doi: 10.1371/journal.pone.0004401) (PMID:19197365) (PMCID:PMC2632744)
Scott, J. (2008) Should I apply for an academic foundation programme? Foundation Years, 4(2), pp. 85-86. (doi: 10.1016/j.mpfou.2008.03.002)
Vereecken, K., Naus, C. W. A., Polman, K., Scott, J. T. , Diop, M., Gryseels, B. and Kestens, L. (2007) Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni. Tropical Medicine and International Health, 12(3), pp. 431-444. (doi: 10.1111/j.1365-3156.2006.01805.x) (PMID:17313515)
Debacker, M., Aguiar, J., Steunou, C., Zinsou, C., Meyers, W. M., Scott, J. T. , Dramaix, M. and Portaels, F. (2004) Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Tropical Medicine and International Health, 9(12), pp. 1297-1304. (doi: 10.1111/j.1365-3156.2004.01339.x) (PMID:15598261)
Debacker, M., Aguiar, J., Steunou, C., Zinsou, C., Meyers, W. M., Guédénon, A., Scott, J. T. , Dramaix, M. and Portaels, F. (2004) Mycobacterium ulcerans Disease (Buruli Ulcer) in Rural Hospital, Southern Benin, 1997–2001. Emerging Infectious Diseases, 10(8), pp. 1391-1398. (doi: 10.3201/eid1008.030886) (PMID:15496239) (PMCID:PMC3320395)
Chatterjee, S., Mbaye, A., Alfidja, A. T., Weyler, J., Scott, J. T. , Van Damme, P., Van De Vijver, K., Deelder, A. and Van Marck, E. A.E. (2004) Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections. Acta Tropica, 90(2), pp. 191-203. (doi: 10.1016/j.actatropica.2003.12.002) (PMID:15177146)
Scott, J. T. , Johnson, R. C., Aguiar, J., Debacker, M., Kestens, L., Guedenon, A., Gryseels, B. and Portaels, F. (2004) Schistosoma haematobium infection and Buruli ulcer. Emerging Infectious Diseases, 10(3), pp. 551-552. (doi: 10.3201/eid1003.020514) (PMID:15116714) (PMCID:PMC3322796)
Scott, J. T. , Vereecken, K., Diakhate, M. M., Vanagt, T., Sambou, V., Diop, M., Ly, A., Vercruysse, J., Gryseels, B. and Kestens, L. (2004) Are the cellular immune responses of children and adults with Schistosoma mansoni infection intrinsically different? Cytokines produced ex vivo in response to antigens and mitogens. Parasite Immunology, 26(1), pp. 29-36. (doi: 10.1111/j.0141-9838.2004.00680.x) (PMID:15198643)
Mduluza, T. et al. (2003) Contrasting cellular responses in Schistosoma haematobium infected and exposed individuals from areas of high and low transmission in Zimbabwe. Immunology Letters, 88(3), pp. 249-256. (doi: 10.1016/S0165-2478(03)00088-9) (PMID:12941484)
Scott, J.T. et al. (2003) Corrigendum. Tropical Medicine and International Health, 8(6), p. 580. (doi: 10.1046/j.1365-3156.2003.01068.x)
Scott, J.T. et al. (2003) Human water contacts patterns in Schistosoma mansoni epidemic foci in northern Senegal change according to age, sex and place of residence, but are not related to intensity of infection. Tropical Medicine and International Health, 8(2), pp. 100-108. (doi: 10.1046/j.1365-3156.2003.00993.x) (PMID:12581433)
Scott, J. T. , Turner, C.M. R., Mutapi, F., Woolhouse, M. E.J., Ndhlovu, P. D. and Hagan, P. (2001) Cytokine responses to mitogen and Schistosoma haematobium antigens are different in children with distinct infection histories. Parasite Immunology, 23(10), pp. 519-526. (doi: 10.1046/j.1365-3024.2001.00409.x) (PMID:11696162)
Scott, J. T. , Turner, C. M. R., Mutapi, F., Woolhouse, M. E.J., Chandiwana, S. K., Mduluza, T., Ndhlovu, P. D. and Hagan, P. (2000) Dissociation of interleukin-4 and interleukin-5 production following treatment for Schistosoma haematobium infection in humans. Parasite Immunology, 22(7), pp. 341-348. (doi: 10.1046/j.1365-3024.2000.00311.x) (PMID:10886718)
Mutapi, F., Ndhlovu, P. D., Hagan, P., Spicer, J. T. , Mduluza, T., Turner, C. M. R., Chandiwana, S. K. and Woolhouse, M. E.J. (1998) Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. Journal of Infectious Diseases, 178(1), pp. 289-293. (doi: 10.1086/517456) (PMID:9652458)
Research Reports or Papers
Scott, J. et al. (2021) ISARIC4C: Multicentre cohort study on symptoms and quality of life following hospitalisation for COVID-19 - preliminary results, 25 February 2021. Documentation. Scientific Advisory Group for Emergencies.
Holgate, S. et al. (2020) Preparing for a challenging winter 2020/21. Technical Report. Academy of Medical Sciences, London.
Conference or Workshop Item
Howlett, P., Walder, A., Lisk, D., N'jai, A., Lado, M., Brown, C., Sevalie, S., Sesay, F.R., Semple, M.G. and Scott, J.T. (2017) Neurological and Psychiatric Manifestations of Post Ebola Syndrome in Sierra Leone. Spring Meeting for Clinician Scientists in Training 2017, London, UK, 23 Feb 2017. S48. (doi: 10.1016/S0140-6736(17)30444-0)
Audio
Scott, J. T. (2016) Ebola epidemic over but flare-ups likely. [Audio]
Scott, J. T. (2015) Can the Ebola virus live on undetected? [Audio]
This list was generated on Thu Apr 18 19:13:56 2024 BST.
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Understanding relapsing remitting Long COVID
Wellcome Trust
2022 - 2023
- Defining and understanding the longer-term effects of COVID-19: A mixed methods study exploring the frequency, nature, and impact of 'long COVID' in the Scottish population.
Office of the Chief Scientific Adviser
2021 - 2023
- Defining and understanding the longer-term effects of COVID-19: A mixed methods study exploring the frequency, nature, and impact of 'long COVID' in the Scottish population.
Public Health Scotland
2021 - 2023
- Glasgow Early Treatment Arm Favipiravir (GETAFIX): a randomised controlled study of favipiravir in COVID-19 hospitalised patients
Chief Scientist Office
2020 - 2021
- Development of an in vitro system for dose and regimen optimisation of therapeutics for Lassa Fever
Tenovus Scotland
2018 - 2020
Media Appearances
BBC The Nine - Wednesday 21 April 2021
Dr Scott appeared on the Wednesday 21 April edition of BBC Scotland's The Nine to discusses the GETAFIX trial testing favipiravir against Covid-19.
Speaking to presenter Martin Geissler about the antiviral drug that she hopes will be effective in treating Covid, Dr Scott said: "Favipiravir was first developed for influenza in Japan and we are hoping it will work for Covid-19.”
BBC Five Live: Lunchtime Show - Wednesday 21 April 2021
Dr Scott was interviewed by Naga Munchetty on the Wednesday 21 April edition of BBC 5 Live's Lunchtime Show, in which they discuss the GETAFIX trial testing favipiravir against Covid-19.
